お知らせ • Apr 23
HK inno.N Corporation to Report Q1, 2026 Results on Apr 28, 2026 HK inno.N Corporation announced that they will report Q1, 2026 results on Apr 28, 2026 Board Change • Apr 22
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Chairman of the Board Yeo-Won Son was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Declared Dividend • Mar 12
Dividend of ₩410 announced Shareholders will receive a dividend of ₩410. Ex-date: 25th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is lower than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 2.3% per year over the past 4 years and payments have been stable during that time. お知らせ • Mar 12
HK inno.N Corporation, Annual General Meeting, Mar 26, 2026 HK inno.N Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 178, osongsaengmyeong-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea お知らせ • Feb 11
HK inno.N Corporation to Report Q4, 2025 Results on Feb 10, 2026 HK inno.N Corporation announced that they will report Q4, 2025 results on Feb 10, 2026 お知らせ • Jul 25
HK inno.N Corporation to Report Q2, 2025 Results on Jul 30, 2025 HK inno.N Corporation announced that they will report Q2, 2025 results on Jul 30, 2025 New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. お知らせ • Apr 22
HK inno.N Corporation to Report Q1, 2025 Results on Apr 28, 2025 HK inno.N Corporation announced that they will report Q1, 2025 results on Apr 28, 2025 Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Executive Director Geun-Seok Song was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. お知らせ • Mar 13
HK inno.N Corporation, Annual General Meeting, Mar 26, 2025 HK inno.N Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 239, osongsaengmyeong 2-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea お知らせ • Mar 12
598 Announces Annual Dividend HK inno.N Corporation announced Annual dividend of KRW 350.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025. お知らせ • Oct 30
HK inno.N Corporation to Report Q3, 2024 Results on Oct 30, 2024 HK inno.N Corporation announced that they will report Q3, 2024 results on Oct 30, 2024 Major Estimate Revision • May 03
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week. Major Estimate Revision • Apr 14
Consensus EPS estimates increase by 19% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week. お知らせ • Mar 14
HK inno.N Corporation, Annual General Meeting, Mar 28, 2024 HK inno.N Corporation, Annual General Meeting, Mar 28, 2024, at 09:01 Korea Standard Time. Upcoming Dividend • Dec 20
Upcoming dividend of ₩320 per share at 0.8% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%). お知らせ • Jul 26
HK inno.N Corporation to Report Q2, 2023 Results on Aug 01, 2023 HK inno.N Corporation announced that they will report Q2, 2023 results on Aug 01, 2023 Board Change • Jun 30
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Chairman, CEO & President Dal-Won Kwak is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Apr 13
Consensus EPS estimates fall by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩320 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%). Price Target Changed • Nov 16
Price target decreased to ₩52,500 Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year. Valuation Update With 7 Day Price Move • May 23
Investor sentiment improved over the past week After last week's 28% share price gain to ₩50,100, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in South Korea. Major Estimate Revision • May 13
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week. 
